Welcome to our dedicated page for Veraxa Biotech - Post de-SPAC SEC filings (Ticker: VRXAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Veraxa Biotech - Post de-SPAC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Veraxa Biotech - Post de-SPAC's regulatory disclosures and financial reporting.
Veraxa Biotech AG - Post de-SPAC (VRXA) has a new Section 16 reporting person: Chief Financial Officer Willener Raju Sudir filed an initial statement of beneficial ownership on Form 3. The filing reports no transactions and does not list any reportable holdings or derivative positions at this time.
Veraxa Biotech AG (VRXA) announced the appointment of Raju Willener as Chief Financial Officer, effective September 4, 2026. He will serve as the company’s principal financial and accounting officer and report to CEO and Co-Founder Christoph Antz, Ph.D.
The company highlights that Mr. Willener brings more than three decades of international experience across investment banking, corporate finance, asset management and strategic leadership, including oversight of investment portfolios exceeding CHF 30 billion in assets under management. Veraxa positions this hire as strengthening its capital markets and financial strategy capabilities as it advances its BiTAC-based oncology pipeline. The company also acknowledges the contributions of former CFO Carl von Halem.
Veraxa Biotech AG (VRXA) director Oliver Rolf Baumann reported an indirect open-market purchase of Veraxa ordinary shares. On 2026-08-27, an entity associated with him, Akira Holding AG, purchased 50,000 Ordinary Shares at $1.50 per share. Following this transaction, Akira Holding AG holds 5,773,618 Veraxa ordinary shares that Baumann may be deemed to beneficially own.
Veraxa Biotech AG (VRXA) reported that Chief Executive Officer and director Christoph Rudiger Antz purchased 5,000 Ordinary Shares on 2026-08-27 in a non-derivative, open-market or private transaction at a price of $1.53 per share. Following this transaction, he directly owns 5,000 Ordinary Shares.
Veraxa Biotech Holding AG (VRXA) reported that VERAXA Biotech AG and Secarna Pharmaceuticals achieved an initial research milestone in their antibody oligonucleotide conjugate (AOC) alliance targeting autoimmune and chronic immune diseases. In early in vitro studies, an AOC candidate created using both companies’ technologies showed greater potency than the equivalent unconjugated oligonucleotide, suggesting enhanced therapeutic potential for targeted delivery. Both companies are now discussing the next steps in the collaboration. VERAXA positions this work as an extension of its antibody-based platforms beyond oncology, while Secarna contributes its AI-enabled OligoCreator platform for oligonucleotide discovery and delivery.
Veraxa Biotech Holding AG (VRXA) filed an initial statement of beneficial ownership (Form 3) for reporting person Carl von Halem, who serves as Interim CFO. The filing does not report any equity transactions or holdings, and no Rule 10b5-1 trading plan is indicated.
AQR Capital Management, LLC, together with AQR Capital Management Holdings, LLC and AQR Arbitrage, LLC, reports its beneficial ownership in Veraxa Biotech Holding AG Ordinary Shares on an amended basis. The group reports beneficial ownership of 658,138 Ordinary Shares, including warrants representing 658,138 Ordinary Shares, par value CHF 100/11,325 per share.
This position represents 0.46% of Veraxa’s outstanding Ordinary Shares. The AQR entities report no sole voting or dispositive power, and shared voting and shared dispositive power over all 658,138 shares. The filing confirms that the AQR group now holds 5% or less of this class of securities.
Veraxa Biotech AG is registering up to 19,436,739 Ordinary Shares issuable upon exercise of outstanding Public and Private Warrants at $11.50 per share. A further 120,295,385 Ordinary Shares and 6,786,739 Private Warrants may be resold from time to time by selling securityholders.
The company will receive no proceeds from these resales and only cash if Warrants are exercised, while holders may elect cashless exercise for Private Warrants. On August 7, 2026, Ordinary Shares closed at $1.99 and Warrants at $0.096, which the company believes makes warrant exercise unlikely while the price is below $11.50.
There were 141,407,813 Ordinary Shares outstanding as of the prospectus date. Veraxa is an oncology-focused biotech with no approved products, an accumulated deficit of CHF 66.6 million, and discloses it is an emerging growth company and a foreign private issuer using home-country Swiss corporate governance practices, which may offer shareholders fewer protections than U.S. domestic issuers.
Veraxa Biotech AG, a Swiss oncology-focused biotechnology company and emerging growth foreign private issuer, has filed a prospectus for the resale of up to 25,000,000 ordinary shares by Lincoln Park Capital Fund under a previously agreed purchase arrangement. These shares include 340,910 commitment shares already issued and up to 24,659,090 shares Veraxa may sell to Lincoln Park over a 24‑month term, tied to a total purchase commitment of up to $50,000,000. Veraxa will not receive proceeds from Lincoln Park’s resale of registered shares but may receive cash from future primary share sales to Lincoln Park under the Purchase Agreement, subject to a Beneficial Ownership Limitation of 4.99%, adjustable to 9.99%. Ordinary shares trade on Nasdaq Global Market under “VRXA” and warrants on Nasdaq Capital Market under “VRXAW.” Assuming all 25,000,000 shares are issued, ordinary shares outstanding would be 166,066,903. Veraxa emphasizes significant operating losses, need for substantial additional capital, clinical and regulatory risks for its oncology pipeline, and governance and disclosure differences arising from its Swiss domicile and foreign private issuer status.